Nick Lydon, Ph.D., FRS, has extensive experience in drug discovery and development and is a recipient of the Lasker Prize and other awards for his achievements in medicine.
Dr. Lydon is a co-founder of AnaptysBio. He is also a co-founder and director of BluePrint Medicines Inc. Dr. Lydon previously served as Vice President, Small Molecule Drug Discovery at Amgen Inc. Prior to joining Amgen, he was the CEO and founder of Kinetix Pharmaceuticals, Inc., a biotechnology company focused on the discovery and development of selective protein kinase inhibitors. Amgen acquired Kinetix in 2000.
Prior to Kinetix, Dr. Lydon worked at CIBA-GEIGY (now Novartis), in Basel, Switzerland, where he was responsible for the tyrosine protein kinase inhibitor program, including the discovery and preclinical development of Imatinib (Gleevec®). He began his pharmaceutical career at Schering-Plough Corporation, where his research involved studies on recombinant interferons.
Dr. Lydon has been awarded the Lasker and Japan Prizes for his work on Imatinib. Other awards include the Warren Alpert Foundation Prize, the AACR-Bruce F. Cain Memorial Award and the Charles F. Kettering Prize from the General Motors Cancer Research Foundation.
Dr. Lydon earned a B.S. in biochemistry and zoology from the University of Leeds, England, and received his Ph.D. in biochemistry from the Medical Sciences Institute, University of Dundee, Scotland.